BridgeMD
New treatment option for Trachea Diseases
Official title Feasibility of Tracheobronchial Defect Reconstruction Using Allogenic Aortic Patch
ClinicalTrials.gov ID: NCT06935110
What this study is testing
- What it's testing
- The investigators investigate the feasibility and safety of using cryopreserved aortic patches for tracheal or bronchial defect repair.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Congenital tracheal deformities: Includes congenital tracheomalacia, congenital tracheobronchial malformations, complete tracheal rings, etc., with...
- Acquired tracheal stenosis: Includes tracheal narrowing caused by diseases, endotracheal intubation, or postoperative scar tissue, with severe...
- Tracheal injury or tissue defect caused by trauma or burns: Cases requiring surgical repair.
- Tracheal tumors: Reconstruction of tracheal tissue following the removal of benign or malignant tumors.
You likely can't join if
- Patients who are unable to provide informed consent.
- Pulmonary tumors that can be treated with standard lobectomy.
- Locally invasive tumors that are unresectable.
- Presence of contralateral lymph node metastasis.
- Presence of distant metastasis, except for solitary, resectable brain metastasis.
- Tracheal lesions amenable to standard resection with direct anastomosis.
See the full eligibility criteria
- Congenital tracheal deformities: Includes congenital tracheomalacia, congenital tracheobronchial malformations, complete tracheal rings, etc., with severe clinical symptoms and cases where treatment is recommended after...
- Acquired tracheal stenosis: Includes tracheal narrowing caused by diseases, endotracheal intubation, or postoperative scar tissue, with severe clinical symptoms and cases where treatment is recommended after evaluation.
- Tracheal injury or tissue defect caused by trauma or burns: Cases requiring surgical repair.
- Tracheal tumors: Reconstruction of tracheal tissue following the removal of benign or malignant tumors.
- Patients who are unable to provide informed consent.
- Pulmonary tumors that can be treated with standard lobectomy.
- Locally invasive tumors that are unresectable.
- Presence of contralateral lymph node metastasis.
- Presence of distant metastasis, except for solitary, resectable brain metastasis.
- Tracheal lesions amenable to standard resection with direct anastomosis.
- Preoperative evaluation indicates inability to undergo standard lobectomy.
- Patients infected with human immunodeficiency virus (HIV) or with other immunodeficiency disorders.
- Any condition or circumstance deemed by the principal investigator to potentially interfere with the conduct of the trial (e.g., severely impaired cardiopulmonary function, significant liver or kidney dysfunction...
- Individuals with concerns about the potential risks of the trial.
The study team makes the final eligibility decision.
Where it's taking place
- Taipei, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taipei, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.